BioSpace News Archive

This award, valued at a total of $999,871 over 29 months, follows the successful completion of the previously announced $150,000 Phase I SBIR for the program.

Visterra is a clinical-stage biotechnology company that uses its novel Hierotope platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines against such targets that are not adequately addressed with conventional approaches.

As part of the agreement, for each year of active sponsorship, Bristol-Myers Squibb can nominate up to three innovative life-sciences and biotech startup companies per year to take up residence in BioLabs’ facilities at 180 Varick Street in Manhattan.

The cash dividend is payable on December 29, 2017, to shareholders of record as of December 15, 2017.

Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.

The program was initiated to help companies and investigators de-risk thawing of frozen cell therapies in early stage clinical trials through to commercialization and point-of-care.

Symbiotix Biotherapies announced the completion of $5 million in institutional financing from Kairos Ventures, LLC.

Aytu BioScience today announced that it presented six posters demonstrating the clinical potential of MiOXSYS, the company’s rapid in vitro diagnostic system for the qualitative measurement of static oxidation-reduction potential (sORP) in human semen, to be used as an aid in the diagnosis of infertility in males.

Baxter announced a new PD-first program for its employees and family members aimed at improving education and awareness of dialysis treatment options, including peritoneal dialysis (PD).

Quark announced that Phase 2 data on its lead program QPI-1002 will be presented as an oral abstract at the American Society of Nephrology (ASN) / Kidney Week being held in New Orleans, LA from October 31 through November 5, 2017.